The AlphaLISA Mouse TNFα Detection Kit is designed for the quantitative determination of mouse TNFα in serum, buffered solution or cell culture medium using a homogeneous (no wash steps, no separation steps) assay.
true falseYou successfully added item(s) to your cart
For research use only. Not for use in diagnostic procedures.
Formats:
Features:
In the mouse, Tumor Necrosis Factor alpha (TNFa) is primarily produced as a homotrimeric 235 amino acid membrane- bound protein. The soluble mature homotrimeric form of 156 amino acids is then released by the metalloprotease TNFa converting enzyme. In humans, TNFa is produced by many cell types like macrophages, monocytes, neutrophils, T cells, and NK cells. It causes cytolysis and cytostasis of many tumor cell lines in vitro. Within hours of injection, TNFa leads to the destruction of small blood vessels within malignant tumors. Although TNFa inhibits the growth of endothelial cells in vitro, it is a potent promoter of angiogenesis in vivo. In contrast to chemotherapeutic drugs, TNFa specifically attacks malignant cells. Furthermore, TNFa is associated with autoimmune disorders, and antibodies directed against TNFa have proven useful.
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
Assay Target | TNFα |
---|---|
Assay Target Class | Cytokine |
Automation Compatible | Yes |
Detection Method | Alpha |
Experimental Type | In vitro |
Product Brand Name | AlphaLISA |
Shipping Condition | Blue Ice |
Target Species | Mouse |
Therapeutic Area | Cancer |
Unit Size | 500 assay points |
The aim of this work was to compare the performance of the AlphaLISA® amplified luminescent proximity homogeneous assay technology platform and an alternative time-resolved fluorescenceresonance energy transfer (TR-FRET) technology assay platform for the detection of five biomarkers.
Immunoassays are a mainstay for the quantification of a variety of bio-molecular analytesin drug discovery, drug development, and life sciences research laboratories. While ELISAs have traditionally been the most popular form of immunoassay, they are limited by the need to perform multiple wash steps.
Immunoassays are used for detection and quantification of low analyte concentrations. Enzyme Linked-Immuno-Sorbent Assay (ELISA) technology is the most widely adopted assays method for performing sandwich or competition based immunoassays.
For the detection of three biomarkers in complex sample matrices, the AlphaLISA and Electrochemiluminescent (ECL) assay technologies were shown to have similar: Assay windows (linear dynamic range), Lower and upper detection limit, Intra-and inter-assay precision (lower % CV) The advantages of using AlphaLISA over ECL are: Shorter total assay duration No wash steps No shaking Lower sample volume requirement for equivalent performance Less expensive instrument and plates required
The AlphaLISA® assay is a homogeneous immunoassay alternative to classical ELISA. AlphaLISA assays were originally utilized to detect analytesin cell cultures upernatants or serum/plasma samples.